Previous Close | 1.0700 |
Open | 1.0600 |
Bid | 0.0000 x 1400 |
Ask | 0.0000 x 1100 |
Day's Range | 1.0100 - 1.0900 |
52 Week Range | 0.5550 - 1.4300 |
Volume | |
Avg. Volume | 401,619 |
Market Cap | 65.082M |
Beta (5Y Monthly) | 1.75 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5600 |
Earnings Date | Oct 31, 2023 - Nov 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for SURF
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special MeetingCAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF) (“Surface”), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) have recommended Surface stockholders vote “FOR” the a
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023. “We are pleased with the progress we have made over the past several months which includes the advancement of the SRF388 and SRF114 clinical trials and the significant efforts we have undertaken towards c
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two clinical stage assets to Coherus' I-O pipeline: SRF388, currently in Phase 2 trials in lung and liver cancer, and SFR114, currently in a Phase 1/2 study as a monotherapy for advanced solid tumors. Coherus will issue shares at $5.2831 per s